Pretherapeutical screening for toxicity-associated polymorphisms in the dihydropyrimidine dehydrogenase gene has been supposed as one possible approach to identify patients at risk during 5-FU-based chemotherapy. It was our central issue to categorize the known single nucleotide polymorphisms c.496A>G, IVS10-15T>C and c.1236G>A regarding their relation to 5-FU toxicity. Our samples were also analyzed for the risk factor c.1129-5923C>G, as it appeared to be linked with c.1236G>A. Moreover, investigating a case of very strong side effects during 5-FU treatment, we found the new splice site mutation IVS12-1G>A.
«
Pretherapeutical screening for toxicity-associated polymorphisms in the dihydropyrimidine dehydrogenase gene has been supposed as one possible approach to identify patients at risk during 5-FU-based chemotherapy. It was our central issue to categorize the known single nucleotide polymorphisms c.496A>G, IVS10-15T>C and c.1236G>A regarding their relation to 5-FU toxicity. Our samples were also analyzed for the risk factor c.1129-5923C>G, as it appeared to be linked with c.1236G>A. Moreover, invest...
»